0 item(s)
View cart
You have no items in your shopping cart.
$260.00
Sku: GMP-TL509-0050
Availability:
AVAILABLE
In stock & estimated to ship in 3-7 days by June 11, 2026
Description
The recombinant human IL-21-Fc fusion protein is an innovative biologics engineered by covalently linking the human IL-21 pleiotropic cytokine with an immunoglobulin Fc domain through genetic recombination technology.
As a γc-chain cytokine family member secreted by antigen-activated CD4+ T cells (including Tfh and Th17 subsets) and NKT cells, IL-21 activates the JAK1/JAK3-STAT1/STAT3 signaling cascade via its heterodimeric receptor complex (IL-21R/γc), orchestrating immune cell functions: potentiating CD8+ T/NK cell-mediated tumor cytotoxicity, promoting Th17 polarization, suppressing Treg differentiation, and driving antibody affinity maturation through coordinated Tfh-B cell interactions.
The Fc fusion design not only extends serum half-life but also enhances immunomodulatory efficacy via Fcγ receptor-mediated targeted delivery, demonstrating unique therapeutic potential in cancer immunotherapy and autoimmune disease intervention.
In cell therapy manufacturing, the recombinant human IL-21-Fc fusion protein serves as a critical culture supplement to enhance the proliferation efficiency and effector cytotoxicity of engineered T/NK cells via JAK-STAT pathway activation, while promoting memory T-cell phenotypes and suppressing activation-induced cell exhaustion (AICD), thereby supporting the generation of highly potent and durable antitumor immune cell products.
Specifications
| Cytokines Details | |
|---|---|
| Synonyms | IL21, Za11, Interleukin-21 |
| Accession | UniProt Q9HBE4-1 |
| Amino Acid Sequence | Gln29–Ser126 |
| Fusion Tag | Human IgG1 Fc fragment fused to the C-terminus |
| Expression System | CHO cells |
| Predicted Molecular Weight | 41.9 kDa |
| Purity | > 95% as determined by SDS-PAGE and HPLC |
| Endotoxin | < 0.01 EU per 1 μg of protein (LAL method) |
| Biological Activity | Induces IFN-γ secretion in human NK-92 lymphoma cells with an ED50 ≤ 50 ng/mL |
| Formulation | Lyophilized from sterile 20 mM phosphate-buffered saline (PBS), pH 7.4, typically containing 6–8% (w/v) mannitol as a stabilizing protectant |
Features
-
✔
Fc-Fusion Enhanced Durability
Human IgG1 Fc fusion extends functional persistence and improves cytokine stability.
-
✔
Potent JAK-STAT Activation
Activates IL-21R/γc–JAK1/JAK3–STAT1/STAT3 signaling for strong immune modulation.
-
✔
High Biological Activity
Demonstrates robust IFN-γ induction in NK-92 cells with low ED₅₀ performance.
-
✔
DMF Filed (039117)
Supports regulatory readiness for GMP cell and gene therapy workflows.
Applications
T Cell Expansion and Effector Enhancement
Promotes proliferation, cytotoxic function, and memory phenotype in engineered T cells.
NK Cell Cytotoxicity Optimization
Enhances NK cell antitumor activity while limiting activation-induced exhaustion.
Cell Therapy Manufacturing
Ideal cytokine supplement for generating potent and durable T/NK cell products.
Cancer Immunotherapy Research
Supports studies focused on immune activation, memory formation, and antitumor efficacy.
Stability & Storage
- √ Lyophilized powder: Stable for 12 months at -80°C or 6 months at -20°C when stored inthe original sealed container under desiccant.
- √ Reconstitution: Dissolve in sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4)maintaining final concentration ≥100 µg/mL to prevent adsorption.
- √ Handling: Aliquot to avoid repeated freeze-thaw cycles.
Cautions
• Research Use Only: This product is not intended for diagnostic or therapeutic use.
• Handling: Follow recommended storage and handling instructions to maintain product stability.
• Support: Contact technical support if assistance is required.
Documents
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
